ABSTRACT-Two patients with acute myeloblastic leukemia (AML) with double minute chromosomes (dmins) are described. One patient had dmins in approximately one-third of bone marrow cells examined at diagnosis; no other karyotypic changes were observed. The dmins disappeared when the patient achieved a complete remission. The second patient developed acute leukemia as a second cancer, having previously received radiotherapy and chemotherapy for a breast carcinoma. At the time of diagnosis of AML, the patient exhibited dmins in 12% of bone marrow cells; other complex karyotypic changes were observed. Data on the clinical and cytogenetic features of these cases are compared with those of other reported cases of acute leukemia with dmins. The possible biologic and clinical significance of dmins in acute leukemia is discussed. -JNCI 1985; 74:1007-1013 Small, paired chromatin bodies known as dmins have been associated with gene amplification; they can be found in cells selected for resistance to certain antimetabolites and in a wide variety of unselected human and animal tumors (1). There have been occasional reports of dmins in human acute leukemia (2-11). We describe here 2 patients with AML with dmins. One patient was a Japanese female with no history of cancer. The other was a Caucasian female who was previously treated with radiotherapy and chemotherapy for a breast carcinoma; in this patient other complex chromosomal changes were observed.
Small, paired chromatin bodies known as dmins have been associated with gene amplification; they can be found in cells selected for resistance to certain antimetabolites and in a wide variety of unselected human and animal tumors (1) . There have been occasional reports of dmins in human acute leukemia (2-11). We describe here 2 patients with AML with dmins. One patient was a Japanese female with no history of cancer. The other was a Caucasian female who was previously treated with radiotherapy and chemotherapy for a breast carcinoma; in this patient other complex chromosomal changes were observed.
MATERIALS AND METHODS
The initial karyotypic analysis was performed on BM cells from both patients before treatment for AML. A second cytogenetic examination was done on patient #1 when a complete remission had been achieved. Metaphase cells were obtained from BM aspirates that were processed directly or after a 24-hour culture period. Karyotypic analysis was also done on an MTX-synchronized BM culture in patient #2 (12) . Metaphase cells were stained conventionally with Giemsa to assess the incidence of cells with dmins. Some slide preparations were destained and then Giemsa-or quinacrine-banded for detailed karyotypic analysis.
CASE REPORTS
Patient #1.-A 68-year-old Japanese woman, in previous good health, was admitted to the Hospital of Hiroshima University School of Medicine on December 24, 1982, for evaluation of fatigue and fever. At that time she was found to have a hemoglobin concentration of 5.5 g/dl, a platelet count of 56.0X 10 9 /liter, and a white blood cell count of 47.7X10 9 /1iter (differential: 33% blasts, 3% promyelocytes, 7% myelocytes, 8% metamyelocytes, 31 % mature neutrophils, and 18% Iymphocytes). The BM was hypercellular and contained 40% blasts and II % promyelocytes with Auer rods. BM cytochemistry was positive for both peroxidase and naphthol AS-D chloroacetate esterase and negative for alpha-naphthyl butyrate esterase. The diagnosis was AML with maturation [M2 according to the French-American-British classification (13) ]. The patient was treated with cytarabine, daunorubicin, vincristine, 6-mercaptopurine, and prednisone, and she achieved a complete remission that lasted 4 months. was negative. The light microscopy and cytochemistry were consistent with a diagnosis of AML, type M1. Since the patient was asymptomatic with stable blood counts, she received no chemotherapy at that time. On December 7, 1981, a BM specimen was hypercellular with 80-90% myeloblasts. She was treated with daunorubicin and cytarabine, but she failed to achieve a complete remission and died of cerebral bleeding on March 3, 1982.
CYTOGENETIC RESULTS
Data on the incidence of dmins in BM cells from both cases at diagnosis of AML are presented in table 1.
Patient #I.-A total of 470 metaphase cells, either unbanded or banded, were scored. In 36.8% of the cells dmins were observed (range, 1-53 dmins/cell). There were no other karyotypic alterations detected in this patient (figs. lA, IB). The percentage of cells with dmins did not differ between the direct and the 24-hour culture preparations. A second karyotypic analysis was performed 2 months later, when the patient had achieved a complete remission. At that time BM cells had a normal 46,XX karyotype with no evidence of dmins in any of the cells examined.
Patient #2.-A total of 161 cells were examined, of which 11.8% exhibited dmins (range, 1-24/cell). Interestingly, the incidence of cells with dmins was much higher in the MTX-synchronized culture preparation than in the direct or routine 24-hour culture preparations (table  1) . Karyotypically, the patient showed two clones. Of the 30 Q-banded cells examined, 11 (36.7%) had a karyotype of 43,XX,-5,-6,-11,-17,-18,+marl,+mar2,del (7)(q32), +0 to 24 dmins (fig. 2 ); dmins were seen in 4 of 11 banded cells with this karyotype. Mar! is a long dicentric or tricentric derivative 6 (possibly 6qter-+6p25: :7pI3?-+7q36?::?). Mar2 is a derivative 17 that may be der(17),t(5;17)(pI3?;p12?). The second, related clone had a karyotype of 48,XX,-5,+6,+8,+8,+11,-17,-18,+mar2, del (7) 
DISCUSSION
In acute leukemia dmins are a relatively rare occurrence. Li (If) reported dmins in 5 of 110 cases (4.5%) of AML, and Rowley (I4) observed dmins in 5 of 150 patients (3.3%) with various types of acute leukemia. The 2 patients described in this report are the only ones with dmins seen by us out of approximately 100 acute leukemia patients at the University of Maryland Cancer Center and 250 at Hiroshima University. alteration present. Hartley and Toolis (4) also described a case of AML that did not exhibit any karyotypic change except for dmins. Li (11) reported 1 patient whose marrow showed two clones: one with dmins but with an otherwise normal karyotype and a second in which dmins were accompanied by trisomy 8. Unlike the karyotype in patient #1, the karyotype in patient #2 was quite complicated with two related clones, one hypodiploid and one hyperdiploid. The dmins were present only in hypodiploid cells. Similarly, most patients with dmins summarized in table 2 had hypodiploid clones and complex karyotypes. The dmins were often accompanied by marker chromosomes and various other numerical and structural aberrations. Loss or partial deletion of the long arm of chromosomes 5 and/or 7 was frequently observed (text- fig. 1 ). The relationship between dmins and these other cytogenetic findings is unclear. Hypodiploid clones with complex karyotypic changes and loss of all or part of #5 and/or #7 are common in secondary acute leukemia and in de novo erythroleukemia (16) (17) (18) . Although many of the patients with dmins summarized herein also had one or the other of these same disease entities, 10 of 19 patients did not (table 2, text- fig. 1 ).
The dmins and their cytologic counterparts, HSR and ABR, are considered to be alternative forms of gene amplification. Thus dmins can integrate into whole chromosomes to form HSR and ABR, and HSR can break down to form dmins (19) (20) (21) . The hypodiploid and hyperdiploid clones in patient #2 appear to be related, since there are several changes (-5, _ -17, -18, mar2, and 7q-) common to each. The dmins were present only in hypodiploid cells, and an alternative intrachromosomal region of DNA amplification might reside within some chromosome (e.g., marl) in the hyperdiploid clone.
The nature of the genes associated with dmins in acute leukemia is not known. In some tumor and leukemia cell JNCI. VOL. 74, NO. 5, MAY 1985 lines HSR, ABR, and/or dmins have been shown to contain amplified copies of certain cellular oncogenes (22) (23) (24) (25) . These novel chromosome abnormalities have also been shown to be associated with amplification of genetic sequences that convey resistance to certain antimetabolites (21, 26, 27) . Since a considerable proportion of acute leukemia patients with dmin have been treated for a previous cancer, dmins in some of these cases may be related to previous exposure to cytotoxic agents. In other patients dmins may represent amplification of genes (e.g., oncogenes) that convey some proliferative growth advantage to the affected leukemia cells. 
